In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maureen Riordan

Senior Deals Analyst

Connecticut, US
Maureen has been with Strategic Transactions for 20 years, first as a Research Analyst, now as a Senior Deals Analyst, with a brief in-between stint as Editor/Contributor for Start-Up company profiles. In her current role, she primarily researches, analyzes, writes, and edits summaries involving current biopharma and medtech deals – which appear in the ST database and the monthly dealmaking section of In Vivo – and also writes and updates legacy deals. Maureen regularly co-authors a quarterly statistics column covering deal trends in both the biopharma and medtech industries for In Vivo. Prior to joining Strategic Transactions, Maureen was a corporate librarian in a management consulting firm fielding search requests for in-house analysts, and then spent two years with Lexis-Nexis as a customer consultant having daily contact with client subscribers to teach database searching techniques. Maureen holds a Bachelor of Arts degree in English from Niagara University, and a Master of Library Science degree from Southern Connecticut State University.
Advertisement
Set Alert for Articles By Maureen Riordan

Latest From Maureen Riordan

Venture Funding Deals: Semma, Arcus Raise $100m-Plus For Cancer, Diabetes Therapies

Semma's $114m Series B round and a $107m Series C for Arcus top November's list of biopharmaceutical venture capital deals. Forty Seven, Medeor and Tricida also closed sizeable rounds.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, December 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.

Deals BioPharmaceutical

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Pacts In Medtech, Sept/Oct 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in September and October 2017.

Pacts in Medtech Deals

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics
See All
Advertisement
UsernamePublicRestriction

Register